774233-60-2

Upstream product

• 20830-81-3 DNR 
• 50700-55-5 1-methyl-2-nitro-1H-imidazole-5-carboxylic acid 
• 864923-96-6 C₁₂H₁₂FN₃O₄ 
• 774233-67-9 C₁₃H₁₂FN₃O₅ 
• 403-01-0 methyl 3-fluoro-4-hydroxybenzoate 
• 65145-13-3 2-fluoro-4-hydroxybenzoic acid 
• 23541-50-6 daunomycin hydrochloride 
• 231950-42-8 5-(bromomethyl)-1-methyl-2-nitro-1H-imidazole 
• 39070-14-9 1-methyl-2-nitro-5-hydroxymethylimidazole 
• 39070-12-7 C₇H₁₁N₃O₂*(x)ClH 

Downstream Products

• 864923-97-7 C₄₂H₄₁FN₄O₁₆ 

Relevant academic research and scientific papers

Compositions and methods for treating cancer

The invention provides a protected anti-neoplastic agent of the formula Hyp-N, wherein N is an anti-neoplastic agent and a protectable hydroxyl group of the anti-neoplastic is substituted with Hyp; Hyp is a moiety having the formula: wherein R 2 is hydrogen; R 3 is hydrogen or C 1 -C 6 alkyl; R 1 is C 1 -C 6 alkyl or C 1 -C 6 alkoxy, optionally substituted with one or more heteroatom-containing groups; and R 4 is hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy, optionally substituted with one or more heteroatom-containing groups.

Hypoxia-Activated Anti-Cancer Agents

Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.